<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EBF9C918-D641-4BC5-9247-BDDA3ADD97E9"><gtr:id>EBF9C918-D641-4BC5-9247-BDDA3ADD97E9</gtr:id><gtr:name>Population Genetics Technologies Limited</gtr:name><gtr:address><gtr:line1>SALISBURY HOUSE</gtr:line1><gtr:city>STATION ROAD</gtr:city><gtr:postCode>CB1 2LA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EBF9C918-D641-4BC5-9247-BDDA3ADD97E9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EBF9C918-D641-4BC5-9247-BDDA3ADD97E9</gtr:id><gtr:name>Population Genetics Technologies Limited</gtr:name><gtr:address><gtr:line1>SALISBURY HOUSE</gtr:line1><gtr:city>STATION ROAD</gtr:city><gtr:postCode>CB1 2LA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>31234.0</gtr:offerGrant><gtr:projectCost>110173.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>48096.0</gtr:offerGrant><gtr:projectCost>48096.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C9CD5016-0EFA-4BB6-9721-65C59D4368DC"><gtr:id>C9CD5016-0EFA-4BB6-9721-65C59D4368DC</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Fordham</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=100972"><gtr:id>E2176E40-3DFA-4930-9AEC-9C56C8ADE433</gtr:id><gtr:title>Pooling Genomes to Analyse Candidate Genomic Regions for Determination of Prognostic Genetic Markers in Patients with Sporadic Renal Cancers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>100972</gtr:grantReference><gtr:abstractText>Population Genetics Technologies Ltd has created a novel workflow to efficiently and cost-effectively sequence candidate genomic regions across large populations using Next-Generation-Sequencing (NGS) sequencing technology. Individually tagged samples are combined into a population library for analysis. Tagging allows sequence changes to be traced to specific individuals in a population so as to compare directly genetic and phenotypic variation, thus providing the basis for discovery of biomarkers to guide therapeutic decisions. PopulationGenetics is applying its technology to candidate genomic regions in samples from well-phenotyped individuals with sporadic clear cell renal cell carcinoma (?ccRCC?). Independently funded studies at the Univerisity of Cambridge will classify the mutations identified according to predicted structural and functional effects with the goal of developing ccRCC biomarkers. The successful application of PopulationGenetics technology to the ccRCC patient cohort will help establish a new paradigm for analysis of populations of biopsied samples based on high throughput sequencing. This new paradigm for the rapid, efficient and inexpensive determination of biomarkers will provide the means for optimal diagnosis and therapy in a variety of disease settings.</gtr:abstractText><gtr:fund><gtr:end>2013-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>79330</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">100972</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>